The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

Diabetic macular edema remains an important cause of vision ... techniques. The Diabetic Retinopathy Clinical Research (DRCR) Network, which includes over 199 participating sites, is currently ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients ...

Three experts discuss the increased mortality risk for patients with diabetic retinopathy, available screening tools, and ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.

In this Healio Video Perspective from Retina 2025, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses positive data for OTX-TKI, a tyrosine kinase inhibitor designed to block VEGFR-1, VEGFR-2 and ...

Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...